Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I

---

Copy For Citation

Agarwal K., Dumas E. O., Gaeta G. B., Lee S., Streinu-Cercel A., Schott E., ...More

67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 11 - 15 November 2016, vol.64

• Publication Type: Conference Paper / Summary Text
• Volume: 64
• City: Massachusetts
• Country: United States Of America
• Istanbul University Affiliated: Yes